Pharmacology of gold compounds in rheumatoid arthritis: A review

Canadian Journal of Clinical Pharmacology

Volumn 4, Issue 3, 1997, Pages 127-136

  Riestra Noriega, Jose L ^b   Harth, Manfred ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b NONE

Author keywords

Cytokines; Gold compounds; Lymphocytes; Monocytes; Polymorphonuclear neutrophils; Rheumatoid arthritis

Indexed keywords

ANTIGEN; ANTIMITOTIC AGENT; COLLAGENASE; GOLD DERIVATIVE; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MITOGENIC AGENT; PHOSPHOLIPASE C; PROTEIN KINASE C;

ANGIOGENESIS; ARTICLE; BONE MARROW APLASIA; CELL ACTIVATION; CELL PROLIFERATION; CHOLESTATIC HEPATITIS; CONCENTRATION RESPONSE; CRANIAL NERVE PARALYSIS; DRUG EFFICACY; DRUG EXCRETION; DRUG URINE LEVEL; ENTEROCOLITIS; ENZYME INHIBITION; HUMAN; IMMUNOMODULATION; INFLAMMATION; LEUKOPENIA; LYMPH NODE; MONOCYTE; NEPHROTIC SYNDROME; NEUTROPHIL; OSTEOLYSIS; PERIPHERAL NEUROPATHY; PHAGOCYTOSIS; PNEUMONIA; PROTEINURIA; RHEUMATOID ARTHRITIS; SKIN MANIFESTATION; SPLEEN; SYNOVIUM; THROMBOCYTOPENIA; TISSUE LEVEL;

EID: 9844262255     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (173)

1. Kean WF, Forestier F, Kassam Y, Buchanan WW, Rooney PJ. The history of gold therapy in rheumatoid disease. Semin Arthritis Rheum 1985;14:180-6.
2. Lande K. Die Gunstige Beeinflussung Schleichender Dauerinfekte durch Solganal. München Med Wochenschrf 1927;74:1132-4.
3. Forestier J. L'aurotherapie dans les rhumatismes chroniques. Bull Mem Hop Paris 1929;53:323-7.
4. Empire Rheumatism Council Research Sub-Committee. Gold therapy in rheumatoid arthritis. Report of a multi-centre controlled trial. Ann Rheum Dis 1960;19:95-117.
5. Sigler JW, Bluhm GB, Duncan H, Sharp JT, Ensign DC, McCrum RW. Gold salts in the treatment of rheumatoid arthritis. A double-blind study. Ann Intern Med 1974;80:21-8.
6. Harth M. Modulation of immune responses by gold salts. Agents Actions Suppl 1981;8:464-76.
7. Gottlieb NL, Gray RG. Pharmacokinetics of gold in rheumatoid arthritis. Agents Actions Suppl 1981;8:529-38.
8. Criswell LA, Redfearn WJ. Variation among rheumatologists in the use of prednisone and second-line agents for the treatment of rheumatoid arthritis. Arthritis Rheum 1994;37:476-80.
9. Collins D, Bellamy N, Campbell J. A Canadian survey of current methotrexate prescribing practices in rheumatoid arthritis. J Rheumatol 1994;21:1220-3.
10. Bellamy N, Brooks PM, Campbell J, Drawe D, Dupren F. An Australian survey of current prescribing practices of methotrexate in rheumatoid arthritis. Aust NZ J Med 1994;24:214-6.
11. Freyberg RH, Block WD, Levey S. Metabolism, toxicity, and manner of action of gold compounds used in the treatment of arthritis. I. Human plasma and synovial fluid concentrations and urinary excretion of gold during and following treatment with gold sodium thiomalate and colloidal gold sulfide. J Clin Invest 1941;20:401-12.
12. Harth M. Methods and problems in determining gold content in body tissues and fluids. Rheumatology 1983;8:20-31.
13. Grootveld MC, Sadler PJ. Differences between the structure of the antiarthritic gold drug "Myochrisin" in the solid state and in solution: a kinetic study of dissolution. J Inorg Biochem 1983;19:51-64.
14. Rudge SR, Perrett D, Swannell AJ, Drury PL. Circulating thiomalate after administration of disodium aurothiomalate: impurity or active metabolite? J Rheumarol 1984;11:150-2.
15. Jellum E, Munthe E, Guldal G, Aaseth J. Fate of the gold and the thiomalate part after intramuscular administration of aurothiomalate to mice. Ann Rheum Dis 1980;39:155-8.
16. Jellum U, Munthe E. Fate of the thiomalate part after intramuscular administration of aurothiomalate in rheumatoid arthritis. Ann Rheum Dis 1982;41:441-2.
17. Rudge SR, Perrett D, Kelly M. Failure of oral thiomalate to act as an alternative to intramuscular gold in rheumatoid arthritis. Ann Rheum Dis 1988;47:224-7.
18. Rudkowski R, Graham GG, Champion GD, Ziegler JB. The activation of gold complexes by cyanide produced by polymorphonuclear leukocytes. I. The effects of aurocyanide on the oxidative burst of polymorphonuclear leukocytes. Biochem Pharmacol 1990;39:1687-95.
19. Graham GG, Dale MM. The activation of gold complexes by cyanide produced by polymorphonuclear leukocytes. II. Evidence for the formation and biological activity of aurocyanide. Biochem Pharmacol 1990;39:1697-702.
20. Lorber A, Bovy RA, Chang CC. Relationship between serum gold content and distribution to serum immunoglobulins and complement. Nature 1972;236:250-2.
21. Kamel H, Brown DH, Ottaway JM, Smith WE. Determination of gold in blood fractions by atomic absorption spectrometry using carbon rod and carbon furace atomisation. Analyst 1976;101:790-7.
22. Lorber A, Vibert GJ, Haaralson AF, Simon TM. I. Unbound serum gold; procedure for quantitation. J Rheumatol 1983;10:563-7.
23. Heath MJ. Measurement of "free" gold in patients receiving sodium aurothiomalate and the high free gold to total gold levels with toxicity. Ann Rheum Dis 1988;47:18-21.
24. Lorber A, Kunishima DH, Harralson AF, Simon TM. II. Unbound versus total serum gold concentration: pharmacological actions on cellular function. J Rheumatol 1983;10:568-73.
25. Smith PM, Smith EM, Gottlieb NL. Gold distribution in whole blood during chrysotherapy. J Lab Clin Med 1973;82:930-7.
26. Schattenkirchner M, Grobenski Z. The measurement of gold in blood and urine by atomic absorption in the treatment of rheumatoid arthritis. Atomic Absorpt News 1977;16:8408.
27. Van de Stadt RJ, Abbo-Tilstra B. Gold binding to blood cells and serum proteins during chrysotherapy. Ann Rheum Dis 1980;39:31-6.
28. Pedersen SM, Graabeck PM. Gold in erythrocytes, whole blood, and plasma during long-term chrysotherapy. Ann Rheum Dis 1980;39:576-9.
29. Graham GG, Havisto TM, McNaught PJ, Browne CD, Champion GD. The effect of smoking on the distribution of gold in blood. J Rheumatol 1982;9:527-31.
30. James DW, Ludvigsen NW, Cleland LG, Milazzo SC. The influence of cigarette smoking on blood gold distribution during chrysotherapy. J Rheumatol 1983;9:532-5.
31. Herrlinger JD, Alsen C, Beress R, Hecker V, Weikert W. Distribution of gold in serum erythrocytes and white blood cells after in vitro incubation and during chrysotherapy with different gold compounds. J Rheumatol 1982;9(Suppl 8):81-9.
32. Gottlieb NL. Comparative pharmacokinetics of parenteral and gold compounds. J Rheumatol 1982;9(Suppl 8):99-109.
33. Furst DE. Single-dose pharmacokinetics of gold compounds. Rheumatology 1983;8:40-51.
34. Mascarenhas BR, Granda JL, Freyberg RH. Gold metabolism in patients with rheumatoid arthritis treated with gold compounds reinvestigated. Arthritis Rheum 1972;391-401.
35. Gerber RC, Paulus HE, Bluestone R, Lederer M. Kinetics of aurothiomalate in serum and synovial fluid. Arthritis Rheum 1972;15:625-9.
36. Gerber RC, Paulus HE, Jennrick RI, et al. Gold kinetics following aurothiomalate therapy; use of whole body radiation counter. J Lab Clin Med 1974;83:778-89.
37. Harth M. Serum gold levels during chrysotherapy with relation to urinary and fecal excretion. Clin Pharmacol Ther 1974;15:354-60.
38. Rubinstein HM, Dietz AA. Serum gold. II. Levels in rheumatoid arthritis. Ann Rheum Dis 1973;32:128-32.
39. 195Au labelled aurothiomalate in blood. Arthritis Rheum 1974;17:171-83.
40. Krusius FE, Markkanen A, Peltola P. Plasma levels and urinary excretion of gold during routine treatment of rheumatoid arthritis. Ann Rheum Dis 1970;29:232-5.
41. Lewis AJ, Walz DT. Immunopharmacology of gold. Prog Med Chem 1982;19:1-58.
42. Weissman MH, Hardison WGM, Walz DT. Studies of the intestinal metabolism of oral gold. J Rheumatol 1980;7:633-8.
43. Intoccia AP, Flanagan TL, Walz DT, et al. Pharmacokinetics of auranofin in animals. J. Rheumatol 1982;9(Suppl 8):90-8.
44. Tepperman K, Finer R, Donovan S, et al. Intestinal uptake and metabolism of auranofin, a new oral gold-based antiarthritis drug. Science 1984;225:430-2.
45. Blocka K, Furst DE, Landaw E, Dromgoole S, Blomberg A, Paulus HE. Single dose pharmacokinetics of auranofin in rheumatoid arthritis. J Rheumatol 1982:9(Suppl 8):110-9.
46. Walz DT, Griswold DE, DiMartino MS, Bumbier EE. Distribution of gold in blood following administration of auranofin (SK&FD-39161). J Rheumatol 1979;6(Suppl 5):56-60.
47. Sharma RP, Smillie J, Palmer DG. Gold concentrations and toxicity during oral gold treatment with auranofin. Pharmacol 1985;30:115-20.
48. Champion GD, Bien D, Browne CT, et al. Auranofin in rheumatoid arthritis. J Rheumatol 1982;9(Suppl 8):137-45.
49. Bertrand JJ, Waine H, Tobias CA. Distribution of gold in the animal body in relation to arthritis. J Lab Clin Med 1948;33:1133-8.
50. Jeffrey MR, Freundlich HF, Bailey DM. Distribution and excretion of radiogold in animals. Ann Rheum Dis 1958;17:52-60.
51. Sharma RP, McQueen EG. The subcellular distribution of gold in monkey liver, kidney, and spleen in vivo. Clin Exp Pharmacol Physiol 1979;6:561-7.
52. Gottlieb NL, Smith PM, Smith EM. Tissue gold concentrations in a rheumatoid arthritic receiving chrysotherapy. Arthritis Rheum 1972;15:16-22.
53. Vernon-Roberts B, Dore JL, Jessop JD, Henderson WJ. Selective concentration and localization of gold in macrophages of synovial and other tissues during and after chrysotherapy in rheumatoid arthritis. Ann Rheum Dis 1976;35:477-86.
54. Gottlieb NL. Gold excretion and retention during auranofin treatment: a preliminary report. J Rheumatol 1979;6(Suppl 5):62-7.
55. Lorber A, Atkins CJ, Chang CC, Lee YB, Starrs J, Bovy RA. Monitoring serum gold values to improve chrysotherapy in rheumatoid arthritis. Ann Rheum Dis 1973;32:133-9.
56. Furst DE, Levine S, Srinivasan R, Metzger AL, Bangert R, Paulus HE. A double-blind trial of high versus conventional dosages of gold salts for rheumatoid arthritis. Arthritis Rheum 1977;20:1473-80.
57. Harth M. Mechanisms of action of disease modifying antirheumatic drugs. J Rheumatol 1992;19(Suppl 32):100-3.
58. Harris ED. Etiology and pathogenesis of rheumatoid arthritis. In: Kelley W, Harris ED, Ruddy S, Sledge LB, eds. Textbook of Rheumatology. Philadephia: WB Saunders, 1993:833-73.
59. Sewell KL, Trentham DE. Pathogenesis of rheumatoid arthritis. Lancet 1993;341:283-6.
60. Koopmans WS, Gay S. Do non-immunologically mediated pathways play a role in the pathogenesis of rheumatoid arthritis? Rheum Dis Clin North Am 1993;19:102-22.
61. Persellin RH, Hess EV, Ziff M. Effect of a gold salt on the immune response. Arthritis Rheum 1967;10:99-106.
62. Taha AS, Sturrock RD, Russell RA. Helicobacter pylori and peptic ulcers in rheumatoid arthritis patients receiving gold, sulfasalazine, and nonsteroidal anti-inflammatory drugs. Am J Gastroenterol 1992;87:1732-5.
63. Okada T, Patterson BK, Ye SQ, Gurney ME. Aurothiolates inhibit HTV-1 infectivity by gold (1) ligand exchange with a component of the virion surface. Virology 1993;192:631-42.
64. Persellin RH, Ziff M. The effect of gold on lysosomal enzymes of the peritoneal macrophage. Arthritis Rheum 1966;9:57-65.
65. Spalding DM, Darby WL, Heck LW. Alterations in macrophage collagenase secretion induced by gold sodium thiomalate. Arthritis Rheum 1986;29:75-81.
66. Penneys NS, Ziboh V, Gottlieb NL, Katz C. Inhibition of prostaglandin synthesis and human epidermal enzymes by aurothiomalate in vitro. Possible actions of gold in pemphigus. J Invest Dermatol 1974;63:356-63.
67. Graabeck PM, Pedersen SM. Effect of two gold compounds on lysosomes. Ann Rheum Dis 1988;47:509-14.
68. Mallya SK, Van Wart HE. Inhibition of human neutrophilic collagenase by gold salts used in chrysotherapy. Biochem Biophys Res Commun 1987;144:101-8.
69. Martel-Pelletier J, Cloutier JM, Pelletier JP. In vitro effects of antirheumatic drugs on neutral collagenolytic proteases in human rheumatoid arthritis cartilege and synovium. J Rheumatol 1988;15:1198-204.
70. Parente JE, Walsh MP, Girard PR, Kuo JF, NG DS, Wong K. Effects of gold on neutrophil function are mediated by inhibition of protein kinase C. Mol Pharmacol 1989;35:26-33.
71. Hashimoto K, Whitehurst CE, Matsubara T, Hirahata K, Lipsky PE. Immunomodulatory effects of therapeutic gold compounds. Gold sodium thiomalate inhibits the activity of T cell protein kinase. J Clin Invest 1992;89:1839-48.
72. Hashimoto K, Whitehurst CE, Matsubara T, Hirahata K, Lipsky PE. Immunomodulatory effects of therapeutic gold compounds. Gold sodium thiomalate and auranofin. J Rheumatol 1994;21:1020-6.
73. Froscio M, Murray AW, Hurst NP. Inhibition of protein kinase C activity by the antirheumatic drug auranofin. Biochem Pharmacol 1989;38:2087-9.
74. Marki F, Stanton JL. Inhibition of human phospholipase C by aurothiomalate and triethyl phospine gold complexes. Arzneimittelforschung 1992;42:328-33.
75. Snyder RM, Mirabelli CK, Clark MA, Ziegler JT, Crooke ST. Effect of auranofin and other gold complexes on the activity of phospholipase C. Mol Pharmacol 1987;32:437-42.
76. Lazarevic MB, Yan K, Swedeler WI, Rasenick MM, Skosey JL. Effect of gold compounds on the activity of adenyl cyclase in human lymphocyte membranes. Arthritis Rheum 1992;35:857-64.
77. Sahinoglu T, Grootveld M, Stevens CR, Thompson SJ, Claxson AW, Blake DR. Influence of disodium aurothiomalate on the activities of xanthine dehydrogenase and xanthine oxidase in endothelial cells. Agents Actions 1991;32(Suppl):71-5.
78. Handel ML, deFazio A, Watts CK, Day RO, Sutherland RL. Inhibition of DNA binding and transcriptional activity of a nuclear receptor transcription factor by aurothiomalate and other metal ions. Mol Pharmacol 1991;40:613-8.
79. Takeuchi F, Hanaoka F, Matsuta K, Miyamoto T. Inhibitory effects of gold sodium thiomalate on DNA polymerase alpha. Clin Exp Rheumatol 1980;7:595-601.
80. Cross CE, Halliwell B, Borish ET, et al. Oxygen radicals and human disease. Ann Rheum Dis 1987;107:526-36.
81. Al Balla S, Johnston C, Davis P. The in vivo effect of nonsteroidal anti-inflammatory drugs, gold sodium thiomalate and methotrexate on neutrophil superoxide radical generation. Clin Exp Rheumatol 1990;8:41-5.
82. Hurst NP, Bell Al, Nuki G. Studies on the effect of d-penicillamine and sodium aurothiomalate therapy on SO production by monocytes from patients with rheumatoid arthritis: evidence for in vivo stimulation of monocytes. Ann Rheum Dis 1986;45:37-43.
83. Finkelstein AE, Ladizesky M, Borisnky R, et al. Antiarthritis synergism of combined oral and parenteral chrysotherapy. Inflammation 1988;12:383-90.
84. Harth M, Keown P, Orange JF. Monocyte-dependent excited oxygen radical generation in rheumatoid arthritis: inhibition by gold sodium thiomalate. J Rheumatol 1983;10:701-7.
85. Harth M, McCain GA, Orange JF. The effects of auranofin and gold sodium thiomalate on the chemiluminescent response of stimulated synovial tissue cells from patients with rheumatoid arthritis. J Rheumatol 1985;12:881-8.
86. Gottlieb NL, Kiem IM, Penneys NS, Schultz DR. The influence of chrysotherapy on serum protein and immunoglobulin levels, rheumatoid factor, and antiepithelial antibody titers. J Lab Clin Med 1975;86:962-70.
87. Niedermeier W, Prillaman WW, Griggs JH. The effect of chrysotherapy on trace metals in patients with rheumatoid arthritis. Arthritis Rheum 1971;14:533-8.
88. Parente JE, Wong K, Davis P, Burka JF, Percy JS. Effects of gold compounds on leukotriene B4, leukotriene C4 and prostaglandin E2 production by poly-morphonuclear leukocytes. J Rheumatol 1986;13:47-51.
89. Honda Z, Lizasa T, Morita Y, Matsuta K, Nishida Y, Miyamoto T. Differential inhibitory effects on leukotriene B4 and leukotriene C formation by human polymorphonuclear leukocytes. Biochem Pharmacol 1987;36:1475-81.
90. Lewis AJ, Carlson RP, Chang J, De Lustro F. Effects of gold salts, and d-penicillamine on type II collagen-induced arthritis in rats. Agents Actions 1984;14:707-14.
91. Lorber A, Simon T, Leeb J, Peter A, Wilcox S. Chrysotherapy. Suppression of immunoglobulin synthesis. Arthritis Rheum 1978;21:785-91.
92. Hanly JG, Hasen J, Whelant A. Effects of gold therapy on the synthesis and quantity of serum and synovial fluid IgM, IgG and IgA rheumatoid factor in rheumatoid arthritis patients. Arthritis Rheum 1986;29:480-7.
93. Pope RM, Lessard J, Nunnery E. Differential effects of therapeutic regimens on specific classes of rheumatoid factor. Ann Rheum Dis 1986;45:183-8.
94. Highton J, Panayi GS, Shepherd D, Faith A, Griffin K, Gibson T. Fall in immune-complex levels during gold treatment of rheumatoid arthritis. Ann Rheum Dis 1981;40:575-80.
95. Olsen N, Ziff M, Jasin HE. Spontaneous synthesis of IgM-RF by blood mononuclear cells from patients with rheumatoid arthritis: effects of treatment with gold salts and d-penicillamine. J Rheumatol 1984;11:17-21.
96. Olsen NS, Jasin HE. Decreased pokeweed mitogen-induced IgM and IgM rheumatoid factor synthesis in rheumatoid arthritis patients treated with gold sodium thiomalate or penicillamine. Arthritis Rheum 1986;27:985-94.
97. Rudge SR, Pound JD, Bossingham DH, Powell RS. Class specific rheumatoid factors in rheumatoid arthritis: response to chrysotherapy and relationship to disease activity. J Rheumatol 1985;12:432-7.
98. Hannonen P, Mottonen T, Teppo AM, Maury CP, Oka M. Class specific rheumatoid factors and their complement binding property in the sera of patients suffering from recent-onset rheumatoid arthritis. Clin Exp Rheumatol 1988;6:121-8.
99. Schultz DR, Volanakis JE, Arnold PI, Gottlieb NL, Sakai K, Stroud RM. Inactivation of C1 in rheumatoid synovial fluid, purified C1 and C1 esterase by gold compounds. Clin Exp Immunol 1974;17:395-406.
100. Burge JJ, Fearon DT, Austen KF. Inhibition of the alternative pathway of complement by gold sodium thiomalate in vitro. J Immunol 78;120:1626-30.
101. Walters MT, Smith JL, Moore J. Changes in tissue and peripheral blood after gold treatment. Ann Rheum Dis 1987;46:7-16.
102. Schweiz P, Warman TG. Cellular immunity in chronic polyarthritis: the effect of basic therapy on T-lymphocyte subpopulations. Schweiz Med Wochenhschr 1983;113:394-8.
103. Lundbergh MS, Cannon GW, Ward JR. Peripheral lymphocyte depletion in gold sodium thiomalate-treated rheumatoid arthritis patients. Arthritis Rheum 1988;31:909-13.
104. Smith MD, Smith A, Fehr M, Ahern MJ, Roberts-Thompson PJ. Effects of chrysotherapy on circulating lymphocyte numbers and subsets. Ann Rheum Dis 1988;47:15-7.
105. Pedersen BK, Abom B. The in vivo effect of auranofin, sodium aurothiomalate and azathioprine on lymphocyte subsets of patients with rheumatoid arthritis. Allergy 1988;43:396-8.
106. Rooney M, Wheland A, Feighery C, Bresnihan B. Changes in synovial membrane mononuclear cell infiltration correlate with rheumatoid factor production by blood mononuclear cells and with the clinical course of rheumatoid arthritis. Arthritis Rheum 1987;30(Suppl):S38. (Abst)
107. Walters K, Smith JL, Moore K, Evans PR, Cawley MD. An investigation on the action of disease-modifying antirheumatic drugs on the rheumatic synovial membrane: reduction in T-lymphocyte subpopulations and HLA-DP and DQ antigen expression after gold or D-Pen therapy. Ann Rheum Dis 1987;46:7-16.
108. Jessop JD, Vernon-Roberts B, Harris J. Effects of gold salts and prednisone on inflammatory cells. I. Phagocytic activity of macrophages and polymorphs in inflammatory exudates studied by a "skin-window" technique in rheumatoid and control patients. Ann Rheum Dis 1973;32:294-300.
109. Vernon-Roberts B, Jessop JD, Dore J. Effects of gold salts and prednisolone on inflammatory cells. E. Suppression of inflammatory and phagocytosis in the rat. Ann Rheum Dis 1973;32:301-7.
110. Hafstrom I, Seligman B, Friedman M, Gallin JI. Auranofin affects early events in human polymorphonuclear neutrophilic activation by receptor-mediated stimuli. J Immunol 1984;132:2007-14.
111. Ghadially FN. The aurosome. J Rheumatol 1979;5:45-50.
112. Miller-Madsen B, Mogensen SC, Dauscher G. Ultrastructural localisation of gold in macrophages and mast cells exposed to aurothioglucose. Exp Mol Pathol 1984;40:148-54.
113. Lipsky PE, Zazuhiro U, Ziff M. Alterations in human monocyte structure induced by incubation with gold sodium thiomalate. J Rheumatol 1979;5:130-6.
114. Scheinberg MA, Santos MB, Finkelstein M. The effect of auranofin and sodium aurothiomalate on peripheral blood monocytes. J Rheumatol 1982;9:366-8.
115. Lipsky PE, Ziff M. Inhibition of antigen and mitogen-induced human lymphocyte proliferation by gold compounds. J Clin Invest 1977;59:455-66.
116. Petersen J. Inhibition of polyclonally-induced immunoglobulin secretion by aurothiomalate. Allergy 1984;39:29-36.
117. Riestra JL, Harth M, Bell DA. Effects of sodium aurothiomalate on the polyclonal immunoglobulin secretion by human mononuclear cells in vitro. J Rheumatol 1988;15:779-84.
118. Drakes M, Harth M, Galsworthy S, McCain GA. Effects of gold on the production of and response to human IL-1. J Rheumatol 1987;14:1123-27.
119. Rordorf-Adam C, Lazdins J, Woods-Cook K, et al. An assay for the detection of interleukin-1 synthesis inhibitors: effects of antirheumatic drugs. Drugs Exp Clin Res 1989;15:355-62.
120. Haynes DR, Garret IR, Whitehouse MW, Vernon-Roberts B. Do gold drugs inhibit interleukin-1? Evidence from an in vitro lymphocyte activating assay. J Rheumatol 1988;15:775-8.
121. Schmidt JA, Abdulla E. Down-regulation of IL-1 beta synthesis by inducers of the heat-shock response. J Immunol 1988;141:2027-34.
122. Connolly KM, Stecher VJ, Danis E, Pruden DJ, Labrie T. Alteration of interleukin-1 activity and the acute phase response in adjuvant arthritic rats treated with disease-modifying antirheumatic drugs. Agents Actions 1988;25:94-105.
123. Remvig L, Enk C, Bligaard N. Effect of auranofin and sodium aurothiomalate on interleukin-1 production from human monocytes in vitro. Scand J Rheumatol 1988;17:255-62.
124. Evans GF, Zuckerman SH. Pharmacologic modulation of TNF production by endotoxin-stimulated macrophages: in vitro and in vivo effects of auranofin and other chrysotherapeutic compounds. Agents Actions 1989;26:329-34.
125. Matsubara T, Saegusa Y, Hirohata K. Low-dose gold compounds inhibit fibroblast proliferation and do not affect interleukin-1 secretion by macrophages. Arthritis Rheum 1988;31:1272-80.
126. Kirkham BW, Navarro FJ, Corkill MM, Panayi GS. In vivo analysis of disease-modifying drug therapy activity in RA by sequential immunohistological analysis of synovial membrane IL-1β. J Rheumatol 1994;21:1615-9.
127. Blitstein-Willinger E, Streller A. In vitro effects of gold sodium thiomalate on IL-1, IL-2 production, IL-2 receptor expression, and IL-2 responsiveness in thymocytes and peripheral blood mononuclear cells. Clin Exp Immunol 1987;68:357-65.
128. Danis VA, Kulesz AJ, Nelson DS, Brooks PM. The effect of gold sodium thiomalate and auranofin on LPs-induced interleukin-1 production by blood monocytes in vitro: variation in healthy subjects and patients with arthritis. Clin Exp Immunol 1990;79:335-40.
129. Riestia-Noriega JL, Rivas MD, Torre JC, Rodrigues A, Arribas JM. Rheumatoid IL-1 inhibitor: a comparison of the effects on the proliferative response and 'in vitro' drug action between healthy subjects and rheumatoid arthritis patients. Br J Rheumatol 1989;27:44-5.
130. Littman BH, Hall RE. Effects of gold sodium thiomalate on functional correlates of human monocyte modulation. Arthritis Rheum 1985;28:1384-92.
131. Littman BH, Schewartz P. Gold inhibition of the production of the second complement component by lymphokine-stimulated human monocytes. Arthritis Rheum 1982;25:288-96.
132. Davies P, Allison AC. Secretion of macrophage enzymes in relation to the pathogenesis of chronic inflammation. In: Nelson DS, ed. Immunology of the Macrophages. New York: Academic Press, 1984:427-61.
133. Kawakami A, Eguchi K, Migita K, et al. Inhibitory effects of gold sodium thiomalate on the proliferation and interferon-gamma-induced HLA-DR expression in human endothelial cells. J Rheumatol 1990;17:430-5.
134. Harth M, Stiller CR, Sinclair NR, Evans J, McGirr D, Zuberi R. Effects of a gold salt on lymphocyte responses. Clin Exp Immunol 1977;27:357-64.
135. Lies RB, Cardin C, Paulus HE. Inhibition by gold on human lymphocyte stimulation. Ann Rheum Dis 1977;36:216-8.
136. Viken KF, Lamvik J. Effects of aurothiomalate on human mononuclear cell cultures in vitro. Acta Pathol Microbiol Scand 1976;84:419-27.
137. Harth M, Stiller CR. Inhibitory effects of gold and other drugs on mononuclear cell responses: a comparison. J Rheumatol 1979;6:(Suppl 5):112-6.
138. Petersen J, Bendtzen K. Immunosuppressive actions of gold compounds. Scand J Rheumatol 1983;16:28-31.
139. Wolf RE, Hall VC. Inhibition of in vitro proliferative response of cultured T-lymphocytes to interleukin-2 by gold sodium aurothiomalate. Arthritis Rheum 1988;31:176-87.
140. Harth M, Couskin K, McCain GA. Sodium aurothiomalate inhibits T-cell response to interleukin-2. Immunopharmacol Immunotoxicol 1988;10:141-56.
141. Sfikakis PP, Souliotis VL, Panayiotidis PP. Suppression of interleukin-2 and interleukin-2 receptor biosynthesis by gold compounds of in vitro activated human peripheral blood mononuclear cells. Arthritis Rheum 1993;36:208-12.
142. Kirkham BW, Davison SC, Corkill MM, Barbatis C, Panayi GS. Serial soluble interleukin-2 receptor levels in rheumatoid arthritis: differences in response to glucocorticoid treatment and chrysotherapy. J Rheumatol 1993;20:935-9.
143. Crilly A, Madhok R, Watson J, Capell HA. Serum concentrations of soluble interleukin-2 receptor in patients with rheumatoid arthritis: effect of second line drugs. Ann Rheum Dis 1993;52:58-60.
144. Harth M, Cousin K, McCain GA. In vitro effects of two gold compounds and d-penicillamine on the production of interferon gamma. Immunopharmacol Imunotoxicol 1990;12:39-60.
145. Harth M, McCain GA, Cousin K. The modulation of interleukin-1 production by interferon gamma, and the inhibitory effects of gold compounds. Immunopharmacol Imunotoxicol 1990;20:125-34.
146. Madhok R, Crilly A, Murphy E, Smith J, Watson J, Capell HA. Gold therapy lowers serum interleukin-6 levels in rheumatoid arthritis. J Rheumatol 1993;20:630-3.
147. Deleuran B, Kristensen M, Paludan KK, et al. The effect of second-line antirheumatic drugs on interleukin-8 mRNA synthesis and protein secretion in human endothelial cells. Cytokine 1992;4:403-9.
148. Russell AS, Nakashima S, Miller C. In vitro boost of human NK activity by a triethyl phosphine gold derivative. Clin Exp Immunol 1984;57:207-10.
149. Aborn B, Pedersen BK. The in vivo effects of trethylphosphine gold (auranofin), sodium aurothiomalate and azathioprine on natural killer cell activity of patients with rheumatoid arthritis. Clin Exp Rheumatol 1987;5:47-52.
150. Kuttan R. Effect of gold thiomalate on cell proliferation and collagen synthesis of synovial cells in culture. Ind J Physiol Pharmacol 1987;31:245-9.
151. Vargas SJ, Jones TG, Hurley MM, Raisz LG. Comparison of the effects of auranofin, gold sodium thiomalate, and penicillamine on resorption of cultured fetal long bones. J Bone Miner Res 1987;2:183-9.
152. Levin JD, Moskowitz MA, Basbaum AI. The effect of gold, in antiarthritis therapy, on substance P levels in rat peripheral nerve. Neurosci Lett 1988;87:200-2.
153. Matsubara T, Ziff M. Inhibition of human endothelial cell proliferation by gold compounds. J Clin Invest 1987;79:1440-6.
154. Koch AE, Cho M, Burrows J, Bovich SS, Polverini SS. Inhibition of production of macrophage-derived angiogenic activity by the antirheumatic agents of gold sodium thiomalate and auranofin. Biochem Biophys Res Commun 1988;154:205-12.
155. Davis P. Undesirable effects of gold salts. J Rheumatol 1979;6(Suppl 5):18-24.
156. Harth M. Gold in rheumatoid arthritis: standard, substitute or sham? J Rheumatol 1993;20:771-3.
157. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyse. Arthritis Rheum 1988;31:702-13.
158. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second line drugs in rheumatoid arthritis. Arthritis Rheum 1992;35:117-25.
159. Harth M, Davis P, Thompson JM, Menard H, Beaudet F. Comparison between sodium aurothiomalate and auranofin in rheumatoid arthritis. Results of a two-year open randomized study. Scand J Rheumatol 1987;16:177-84.
160. Schattenkirchner M, Broll H, Kaik B, Muller-Fassbender H, Rau R, Zeidler H. Auranofin, and gold sodium thiomalate in the treatment of rheumatoid arthritis: a one-year double-blind comparative multicenter study. Klin Wochenschr 1988;66:167-74.
161. Bendix G, Bjelle A. A 10-year follow-up of parenteral gold therapy in patients with rheumatoid arthritis. Ann Rheum Dis 1996;55:169-76.
162. Stein HB, Urowitz MB. Gold-induced enteroeolitis, case report and literature review. J Rheumatol 1976;3:21-6.
163. Favreau M, Tannenbaum H, Lough J. Hepatotoxicity associated with gold therapy. Ann Intern Med 1977;87:717-9.
164. Gould PW, McCormack PL, Palmer DG. Pulmonary damage associated with sodium aurothiomalate therapy. J Rheumatol 1977;4:252-60.
165. Fam AG, Gordon DR, Sarkozi J, et al. Neurologic complications associated with gold therapy for rheumatoid arthritis. J Rheumatol 1984;14:700-6.
166. Ward JR, Williams J, Egger MJ, et al. Comparison of auranofin, gold sodium thiomalate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1983;26:1303-15.
167. Wolfe F, Hawley DJ, Cathey MA. Termination of slow-acting anti-rheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990;17:994-1002.
168. Denman EJ, Denmar AM. The lymphocyte transformation test and gold hypersensitivity. Ann Rheum Dis 1968;27:582-4.
169. Romagnoli P, Spinas GA, Sinigaglia F. Gold specific T-cells in rheumatoid arthritis patients treated with gold. J Clin Invest 1992;80:254-308.
170. Harth M, Hickey JP, Coulter WK, Thompson JM, Disney TF. Gold-induced thrombocytopenia. J. Rheumatol 1978;5:165-72.
171. Wooley PH, Griffin J, Panayi GS, Batcheldor JR, Welsh KI, Gibson TJ. HLA-DR antigens and toxic reactions to sodium aurothiomalate and d-penicillamine in patients with rheumatoid arthritis. N Engl J Med 1980;303:300-2.
172. Singal DP, Reid B, Green D, D'Souza M, Bensen WG, Buchanan WW. Polymorphism of major histocompatibility complex extended haplotypes bearing HLA-DR3 in patients with rheumatoid arthritis with gold-induced thrombocytopenia or proteinuria. Ann Rheum Dis 1990;49:582-6.
173. Madhok R, Capell HA, Waring R. Does sulfoxidation state predict gold toxicity in rheumatoid arthritis? BMJ 1987;294:483.